Preview Interactive Learning

Our Interactive Learning program has been designed to promote critical thinking in the application of knowledge to optimize care for patients with diabetes. Each interactive learning module is presented in the following manner:

Start with the case.

Vote to voice your perspective.

Watch a video with one of our experts.

Take away valuable resources from the Toolbox.

Discuss the topic with other pharmacists.

 
New! Receive a Certificate of Participation after completing the Interactive Learning Evaluation for each module.

Below is a preview of the Interactive Learning module content, available to members only. Log in or sign up today for full access.

 

Preconception Care in Women with Diabetes: What Do Pharmacists Need to Know?

Women with diabetes who become pregnant are at risk of higher rates of complications than the general population. Preconception care involves recognizing and addressing biomedical and behavioral issues that may pose a risk to the health of a woman or fetus. These interventions should ideally occur prior to conception and can significantly reduce the risk of complications almost to the level as for women without diabetes. Unfortunately less than 50% of women receive such care and vulnerable populations are at the highest risk. In this module, we explore the ways pharmacists can identify women of childbearing potential and educate them on preconception care. ‎

Developed: January 2017

Sample video clip from the module:

To access the full module, log in or sign up today.

 

Where is the Profession of Pharmacy Headed?

The pharmacy profession is evolving from the safe distribution of medications to the delivery of patient-centred care. Despite continuous efforts to enhance pharmacy practice, many pharmacists are still unable to practise to their full scope. This learning module will explore the current barriers that pharmacists face, including system, workplace, education and individual level barriers, as well as priorities to advance the pharmacy profession over the next decade.

Developed: November 2016

Sample video clip from the module:

To access the full module, log in or sign up today.

 

SGLT2 Inhibitors: What Do Pharmacists Need To Know?

Canagliflozin, dapagliflozin, and empagliflozin belong to the class of antihyperglycemic agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors. Their ability to lower A1C, weight, and blood pressure without causing hypoglycemia makes them appealing options in diabetes management. However, reports from the Food and Drug Administration, European Medicines Agency, and Health Canada regarding the safety of SGLT2 inhibitors warrant a discussion about the risks and benefits of these agents. This module will discuss key areas, some of which have led to confusion, about this new class of antihyperglycemic agents.

Developed: May 2016

Sample video clip from the module:

To access the full module, log in or sign up today.

 

Initiation & Titration of Insulin in Type 2 Diabetes

As type 2 diabetes is characterized by the progressive decline in pancreatic β-cell function, many patients will eventually require insulin to achieve glycemic control. According to the Diabetes Mellitus Status in Canada (DM-SCAN) survey, approximately 60% of those with type 2 diabetes receiving antihyperglycemic therapy were using insulin. Despite this, more than half of the individuals were not meeting the recommended A1C target of ≤7.0%. Pharmacists have the unique opportunity to address the barriers related to insulin and help patients achieve glycemic control.

Developed: January 2016

Sample video clip from the module:

To access the full module, log in or sign up today.

 

Should Every Patient with Diabetes ≥ 55 Years of Age Receive an Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin II Receptor Blocker (ARB)?

According to the CDA 2013 Clinical Practice Guidelines, ACE inhibitors or ARBs should be used in all individuals with diabetes who are 55 years of age or older. This recommendation is based on Grade A, Level 1 evidence for those with an additional risk factor or end organ damage, and Grade D, Consensus, for all others. This recommendation is applied differently by different prescribers, particularly for patients that are normotensive and have normoalbuminuria. Participate in this module to explore this issue further based on benefit and risk assessments.

Developed: October 2015

Sample video clip from the module:

To access the full module, log in or sign up today.

 

Individualizing Drug Therapy in Patients with Diabetes and Chronic Kidney Disease (CKD)

Up to half of patients with diabetes will demonstrate signs of kidney disease in their lifetime. It is very important to individualize drug therapy in patients with diabetes and chronic kidney disease. Participate in this module and explore this issue.

Developed: September 2015

Sample video clip from the module:

To access the full module, log in or sign up today.